ESSEX BIO-TECH(01061),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

01061 ESSEX BIO-TECH

Closed 06-25 16:08:06

2.700

+0.000

0.00%

High2.700	Low2.610	Vol353.00K
Open2.700	D1 Closing2.700	Amplitude3.33%
Mkt Cap1.53B	Tradable Cap1.53B	Total Shares566.00M
T/O932.20K	T/O Rate0.06%	Tradable Shares566.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"01061","market":"HK","secType":"STK","nameCN":"ESSEX BIO-TECH","latestPrice":2.7,"timestamp":1782374886540,"preClose":2.7,"halted":0,"volume":353000,"delay":0,"changeRate":0,"floatShares":566000000,"shares":566000000,"eps":0.561,"marketStatus":"Closed","change":0,"latestTime":"06-25 16:08:06","open":2.7,"high":2.7,"low":2.61,"amount":932200,"amplitude":0.033333,"askPrice":2.7,"askSize":7000,"bidPrice":2.64,"bidSize":51000,"shortable":0,"etf":0,"ttmEps":0.561,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1782437400000},"marketStatusCode":5,"adr":0,"listingDate":993571200000,"exchange":"SEHK","adjPreClose":2.7,"dividendRate":0.051852,"openAndCloseTimeList":[[1782351000000,1782360000000],[1782363600000,1782374400000]],"volumeRatio":0.918314,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01061","defaultTab":"news","newsList":[{"id":"1143920686","title":"Essex Bio-Technology Executes HKD0.26 Million On-Market Share Buyback, Boosting Treasury Stock to 0.12% of Issued Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=1143920686","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1143920686?lang=en_us&edition=fundamental","pubTime":"2026-06-25 17:04","pubTimestamp":1782378297,"startTime":"0","endTime":"0","summary":"Essex Bio-Technology Limited reported that it repurchased 100,000 ordinary shares on 25 June 2026, paying an aggregate HKD0.26 million at prices ranging between HKD2.63 and HKD2.64 per share. The...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01061"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138116449","title":"ESSEX BIO-TECH Executes Share Buyback, Spending HK$648,700","url":"https://stock-news.laohu8.com/highlight/detail?id=1138116449","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1138116449?lang=en_us&edition=fundamental","pubTime":"2026-06-24 17:08","pubTimestamp":1782292115,"startTime":"0","endTime":"0","summary":"Pharmaceutical firm ESSEX BIO-TECH (HKEX: 01061) has disclosed details of a recent share repurchase transaction.The company announced that on June 24, 2026, it purchased approximately 247,000 of its own shares on the market.The total expenditure for this buyback operation was around HK$648,700.","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","01061"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645896591","title":"Essex Bio-technology Files HKEX Next-day Disclosure Return on Share Repurchase for Cancellation","url":"https://stock-news.laohu8.com/highlight/detail?id=2645896591","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645896591?lang=en_us&edition=fundamental","pubTime":"2026-06-24 17:05","pubTimestamp":1782291922,"startTime":"0","endTime":"0","summary":"Essex Bio-Technology files HKEX next-day disclosure return on share repurchase for cancellationEssex Bio-Technology repurchased 247,000 ordinary shares on June 24 for treasury, paying HKD 2.61–2.64 ea","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260624:nNDL82QzHt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","01061"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154132495","title":"Essex Bio-Tech repurchases 120,000 shares; treasury stock rises to 0.33 million units","url":"https://stock-news.laohu8.com/highlight/detail?id=1154132495","media":"Bulletin Express","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1154132495?lang=en_us&edition=fundamental","pubTime":"2026-06-23 17:03","pubTimestamp":1782205428,"startTime":"0","endTime":"0","summary":"Essex Bio-Technology Limited reported a share repurchase of 120,000 ordinary shares on 23 June 2026 via on-market transactions at prices between HKD 2.63 and HKD 2.65, implying a volume-weighted...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01061"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139639718","title":"ESSEX BIO-TECH Repurchases Shares, Spending HK$317,300 on June 23","url":"https://stock-news.laohu8.com/highlight/detail?id=1139639718","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1139639718?lang=en_us&edition=fundamental","pubTime":"2026-06-23 17:03","pubTimestamp":1782205382,"startTime":"0","endTime":"0","summary":"On June 23, ESSEX BIO-TECH (01061) announced it had executed a share repurchase. The company bought back 120,000 of its own shares, utilizing a total of HK$317,300 in the transaction.","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01061","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645588109","title":"Essex Bio-Technology files HKEX next-day return disclosing share repurchase for treasury shares at HKD 2.64 each","url":"https://stock-news.laohu8.com/highlight/detail?id=2645588109","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645588109?lang=en_us&edition=fundamental","pubTime":"2026-06-23 16:55","pubTimestamp":1782204928,"startTime":"0","endTime":"0","summary":"Essex Bio-Technology repurchased 120,000 ordinary shares on June 23, 2026 for treasury, no shares cancelled.Buyback price ranged HKD 2.63 to HKD 2.65 per share; aggregate consideration HKD 317,280.Issued shares excluding treasury fell to 566,680,000; treasury shares rose to 326,000.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Essex Bio-Technology Limited published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange  , on June 23, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260623:nNDLccK15h:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","01061"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146950232","title":"Essex Bio-Technology Buys Back 71,000 Shares; Outstanding Share Count Trimmed to 566.80 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=1146950232","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1146950232?lang=en_us&edition=fundamental","pubTime":"2026-06-22 17:04","pubTimestamp":1782119074,"startTime":"0","endTime":"0","summary":"Essex Bio-Technology Limited reported the repurchase of 71,000 ordinary shares on 22 June 2026 via on-market transactions on the Hong Kong Stock Exchange. • Transaction details: Purchase prices...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01061"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137652100","title":"ESSEX BIO-TECH Repurchases 71,000 Shares for HK$186,400","url":"https://stock-news.laohu8.com/highlight/detail?id=1137652100","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1137652100?lang=en_us&edition=fundamental","pubTime":"2026-06-22 16:55","pubTimestamp":1782118541,"startTime":"0","endTime":"0","summary":"ESSEX BIO-TECH (HKEX: 01061) has executed a share buyback transaction. On June 22, 2026, the company allocated HK$186,400 to repurchase 71,000 of its own shares.The purchase price for the shares ranged between HK$2.62 and HK$2.64 per share.","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01061","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645040435","title":"Essex Bio-Tech files HKEX next-day return disclosing share repurchase at HKD 2.64-2.62","url":"https://stock-news.laohu8.com/highlight/detail?id=2645040435","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645040435?lang=en_us&edition=fundamental","pubTime":"2026-06-22 16:50","pubTimestamp":1782118252,"startTime":"0","endTime":"0","summary":"Essex Bio-Technology repurchased 71,000 ordinary shares on June 22 for treasury, paying HKD 2.62–2.64 per share.Aggregate consideration totaled HKD 186,440; shares repurchased for cancellation: 0.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Essex Bio-Technology Limited published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange  , on June 22, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nNDL3DRbYS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","01061"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137415461","title":"ESSEX BIO-TECH Executes HKD0.36 Million Share Buyback, Reducing Free Float by 0.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=1137415461","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1137415461?lang=en_us&edition=fundamental","pubTime":"2026-06-18 18:46","pubTimestamp":1781779581,"startTime":"0","endTime":"0","summary":"Essex Bio-Technology Limited reported the repurchase of 135,000 ordinary shares on 18 June 2026, according to its Next Day Disclosure Return filed with the Hong Kong Stock Exchange. The shares were...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01061"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116837708","title":"Essex Bio-Tech Executes Share Buyback, Spending HK$356,600","url":"https://stock-news.laohu8.com/highlight/detail?id=1116837708","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1116837708?lang=en_us&edition=fundamental","pubTime":"2026-06-18 18:45","pubTimestamp":1781779518,"startTime":"0","endTime":"0","summary":"Essex Bio-Tech (HKEX: 01061) has announced a share repurchase transaction.The company disclosed that on June 18, 2026, it utilized approximately HK$356,600 to buy back 135,000 of its own shares.The repurchase was conducted at a price range between HK$2.63 and HK$2.65 per share.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01061","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643052756","title":"Shanghai Henlius Biotech Says Phase 3 Study Of HLX04-O For WAMD Meets Primary Endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2643052756","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643052756?lang=en_us&edition=fundamental","pubTime":"2026-06-16 18:46","pubTimestamp":1781606799,"startTime":"0","endTime":"0","summary":"June 16 (Reuters) - Shanghai Henlius Biotech Inc <2696.HK>::*PHASE 3 STUDY OF HLX04-O FOR WAMD MEETS PRIMARY ENDPOINT*Further company coverage: 2696.HK* ((Reuters.Briefs@thomsonreuters.com;))  ((Reute","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nRSD6sxYgs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","HK0000306685.HKD","02696","BK1230","HK0000320223.HKD","HK0000165453.HKD","00656","01061","HK0000306701.USD","HK0000320264.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643756031","title":"Henlius Biotech's Trial of Macular Degeneration Drug Meets Primary Endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2643756031","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643756031?lang=en_us&edition=fundamental","pubTime":"2026-06-16 18:46","pubTimestamp":1781606772,"startTime":"0","endTime":"0","summary":"Shanghai Henlius Biotech's  phase 3 study of HLX04-O in patients with wet age-related macular degeneration met its primary study endpoint, according to a Tuesday filing with the Hong Kong bourse.HLX04-O had a good safety profile, with similar overall, ocular and non-ocular safety results compared to ranibizumab.The drug is a new ophthalmic preparation product developed based on Hanbeitai, the exclusive rights of which for ophthalmic treatment and therapy worldwide have been granted by the company to Essex Bio-Technology  and Zhuhai Essex Bio-Pharmaceutical.The company has an agreement to co-develop the relevant product with Essex Bio-Technology.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["HK0000320264.USD","BK4581","HK0000306701.USD","HK0000320223.HKD","BK4585","02696","BK1161","BK4588","HK0000306685.HKD","XBI","HK0000165453.HKD","01061"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643532567","title":"Essex Bio-Technology’s HLX04-O Hits Phase 3 Endpoint in Wet-AMD Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2643532567","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643532567?lang=en_us&edition=fundamental","pubTime":"2026-06-16 17:40","pubTimestamp":1781602819,"startTime":"0","endTime":"0","summary":"An update from Essex Bio-Technology ( ($HK:1061) ) is now available. Essex Bio-Technology announced that AURA-2, a multi-centre phase 3 trial of HL...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/essex-bio-technologys-hlx04-o-hits-phase-3-endpoint-in-wet-amd-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/essex-bio-technologys-hlx04-o-hits-phase-3-endpoint-in-wet-amd-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["01061","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643062730","title":"Essex Bio-Tech says AURA-2 Phase III trial of HLX04-O for wet AMD meets primary endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2643062730","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643062730?lang=en_us&edition=fundamental","pubTime":"2026-06-16 17:14","pubTimestamp":1781601274,"startTime":"0","endTime":"0","summary":"Essex Bio-Technology reported its AURA-2 Phase 3 study of HLX04-O for wet age-related macular degeneration met its primary endpoint.Results have already been generated; the announcement did not indicate any future presentation schedule.HLX04-O showed comparable vision outcomes to ranibizumab, supporting a non-inferiority profile in the head-to-head trial.Safety was broadly similar between treatment arms, with no new overall concerns highlighted.The company cited global 2025 sales of wet AMD drugs at about USD 13.31 billion, underscoring the market opportunity.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Essex Bio-Technology Limited published the original content used to generate this news brief via IIS, the regulatory disclosure sys","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nNDL832jZm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","01061"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122040423","title":"ESSEX BIO-TECH Reports Stable Share Capital and Confirms Public Float Compliance for May 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1122040423","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1122040423?lang=en_us&edition=fundamental","pubTime":"2026-06-02 12:23","pubTimestamp":1780374193,"startTime":"0","endTime":"0","summary":"Essex Bio-Technology Limited (ESSEX BIO-TECH) filed its Monthly Return for the period ended 31 May 2026, showing no movement in either authorised or issued share capital. Authorised Share Capital   •...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01061"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637374427","title":"Essex Bio-Technology Limited (HKG:1061) Looks Interesting, And It's About To Pay A Dividend","url":"https://stock-news.laohu8.com/highlight/detail?id=2637374427","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637374427?lang=en_us&edition=fundamental","pubTime":"2026-05-24 08:44","pubTimestamp":1779583447,"startTime":"0","endTime":"0","summary":"Essex Bio-Technology Limited ( HKG:1061 ) is about to trade ex-dividend in the next three days. The ex-dividend date is...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1061/essex-bio-technology-shares/news/essex-bio-technology-limited-hkg1061-looks-interesting-and-i","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1061/essex-bio-technology-shares/news/essex-bio-technology-limited-hkg1061-looks-interesting-and-i","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4588","VIG","BK4585","01061","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150350482","title":"Essex Bio-Tech: April 2026 Monthly Return Shows Stable Share Capital and Full Public Float Compliance","url":"https://stock-news.laohu8.com/highlight/detail?id=1150350482","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1150350482?lang=en_us&edition=fundamental","pubTime":"2026-05-04 17:02","pubTimestamp":1777885365,"startTime":"0","endTime":"0","summary":"Essex Bio-Technology Limited filed its Monthly Return for the period ended 30 April 2026, confirming that both authorised and issued share capital remained unchanged during the month. The company’s...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01061"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127053235","title":"ESSEX BIO-TECH 2025年度营收增长8.6%，三大业务板块表现稳健","url":"https://stock-news.laohu8.com/highlight/detail?id=1127053235","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1127053235?lang=en_us&edition=fundamental","pubTime":"2026-03-31 16:53","pubTimestamp":1774947228,"startTime":"0","endTime":"0","summary":"ESSEX BIO-TECH于2025财政年度（截至2025年12月31日）录得综合营业额约港币1,813.8百万，同比上升8.6%，同期净利润约港币318.1百万，同比增长3.5%。公司主要收入来自中国内地市场，折算人民币计，全年收入约为人民币16.72亿元，净利润约人民币2.93亿元。旗舰生物制剂Beifushu®和Beifuji®系列合计占总营业额约83.5%，继续成为主要业绩增长的动力。...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01061"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195907302","title":"ESSEX BIO-TECH unveils AGM agenda: HK$0.07 final dividend, 20% share issue mandate, 10% buy-back authority","url":"https://stock-news.laohu8.com/highlight/detail?id=1195907302","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1195907302?lang=en_us&edition=fundamental","pubTime":"2026-03-31 16:47","pubTimestamp":1774946831,"startTime":"0","endTime":"0","summary":"ESSEX BIO-TECH has released its 2026 AGM circular outlining key resolutions to be tabled on 26 May 2026 in Hong Kong. Dividend   • Board proposes a cash final dividend of HK$0.07 per share for FY...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01061"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.essexbio.com","stockEarnings":[{"period":"1week","weight":-0.0146},{"period":"1month","weight":-0.0753},{"period":"3month","weight":-0.2299},{"period":"6month","weight":-0.2893},{"period":"1year","weight":-0.4151},{"period":"ytd","weight":-0.2667}],"compareEarnings":[{"period":"1week","weight":-0.037},{"period":"1month","weight":-0.0857},{"period":"3month","weight":-0.0581},{"period":"6month","weight":-0.0932},{"period":"1year","weight":-0.0316},{"period":"ytd","weight":-0.0866}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Essex Bio-Technology Ltd is an investment holding company mainly engaged in the production and sale of biopharmaceuticals for the treatment of body surface trauma and eye injuries. The Company operates its business through three segments. The Surgical segment is engaged in the development, manufacture and sale of Beifuji series products such as Beifuji spray, Beifuji lyophilized powder, Beifuxin gel and others. The Ophthalmology segment is engaged in the development, manufacture and sale of Beifuji series products such as Beifushu eye drops, Beifushu eye gel, Beifushu single-dose eye drops and others. The Provision of Services segment is engaged in the provision of healthtech e-platform related medical services.","yearOnYearQuotes":[{"month":1,"riseRate":0.733333,"avgChangeRate":0.036282},{"month":2,"riseRate":0.6,"avgChangeRate":0.051619},{"month":3,"riseRate":0.533333,"avgChangeRate":0.042805},{"month":4,"riseRate":0.466667,"avgChangeRate":0.031977},{"month":5,"riseRate":0.4,"avgChangeRate":-0.012005},{"month":6,"riseRate":0.4,"avgChangeRate":0.023156},{"month":7,"riseRate":0.357143,"avgChangeRate":-0.026551},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.002168},{"month":9,"riseRate":0.533333,"avgChangeRate":0.03471},{"month":10,"riseRate":0.333333,"avgChangeRate":0.013996},{"month":11,"riseRate":0.466667,"avgChangeRate":0.008914},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.018984}],"exchange":"SEHK","name":"ESSEX BIO-TECH","nameEN":"ESSEX BIO-TECH"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ESSEX BIO-TECH(01061),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest ESSEX BIO-TECH(01061) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"ESSEX BIO-TECH,01061,ESSEX BIO-TECH股票,ESSEX BIO-TECH股票老虎,ESSEX BIO-TECH股票老虎国际,ESSEX BIO-TECH行情,ESSEX BIO-TECH股票行情,ESSEX BIO-TECH股价,ESSEX BIO-TECH股市,ESSEX BIO-TECH股票价格,ESSEX BIO-TECH股票交易,ESSEX BIO-TECH股票购买,ESSEX BIO-TECH股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ESSEX BIO-TECH(01061),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest ESSEX BIO-TECH(01061) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}